



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



May 26, 2026

Corporate Relations
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Dear Sir,

Sub: Outcome of Board Meeting and Financial Results - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Ref: Scrip Code 506414

We write to inform you that the Board of Directors of the Company at its meeting held on May 26, 2026 has, *inter alia*,

1. Audited Financial Results:

Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026 as per Regulation 33 of the Listing Regulations.

The Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026 along with the Auditors' Reports with unmodified opinion on the aforesaid Audited Financial Results (Standalone and Consolidated) issued by the Statutory Auditors, SRBC & Co. LLP, Chartered Accountants, dated May 26, 2026 are enclosed herewith.

2. Annual General Meeting (AGM):

Approved that the 74th Annual General Meeting ('AGM') of the members of the Company will be held on Tuesday, August 11, 2026 through Video Conferencing or Other Audio-Visual Means, in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

The Notice of AGM, Board's Report and the Annual Report for the Financial Year 2025-26 shall be sent to the members within the statutory time limits.

3. Final Equity Dividend:

Recommended final equity dividend at Rs. 3.75/- (Rupees Three and Paise Seventy Five only) per equity share of Rs. 5/- each (i.e. 75%) for the financial year ended March 31, 2026, for members' approval.



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



Pursuant to Regulation 30 and 43 of the Listing Regulations, the aforementioned final equity dividend, if approved at the aforesaid AGM of the Company, will be paid to the members of the Company on or before Friday, August 21, 2026.

4. Record Date for Equity Dividend:

Approved Wednesday, August 5, 2026 as the Record Date, pursuant to Regulation 42 of the Listing Regulations, fixed for the purpose of payment of final equity dividend for the financial year 2025-26 as may be approved by the Members of the Company at the aforesaid AGM scheduled to be held on Tuesday, August 11, 2026.

Kindly take the above on record.

The Board meeting commenced at 01:00 p.m. (IST) and concluded at 02:00 p.m. (IST).

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

Varadvinayak Khambete

Company Secretary & Head - Legal

Membership No. A33861

Encl: As above

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
**The Board of Directors of
Fermenta Biotech Limited**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended March 31, 2026 and for the year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.



SRBC & COLLP

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



S R B C & C O L L P

Other Matter

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us as required under the Listing Regulations.

For S R B C & C O L L P

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

Poonam Tadarwal



per Poonam Tadarwal
Partner

Membership No.: 136454

UDIN: 26136454ARMUJN8904

Mumbai

May 26, 2026




Fermenta Biotech Limited
CIN:L99999MH1951PLC008485
Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
Tel:+91-22-67980888, Fax:+91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

₹ in Lakhs


Sr. No.	Particulars	Standalone			
		Quarter Ended		Year Ended	
		Audited March 31, 2026	Unaudited December 31, 2025	Audited March 31, 2025	Audited March 31, 2026
1	Income				
	a) Revenue from operations (refer note 4)	10,987.63	11,424.25	12,203.79	45,025.27
	b) Other income	609.88	343.14	388.30	2,389.89
2	Total Income (a+b)	11,597.51	11,767.39	12,592.09	47,415.16
3	Expenses				
	a) Cost of materials consumed (refer note 6)	3,641.51	4,909.19	3,774.60	16,656.99
	b) Purchases of stock-in-trade	231.73	563.52	716.84	1,150.05
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(384.66)	(1,504.94)	(35.16)	(2,470.98)
	d) Employee benefits expense	1,832.04	1,811.85	1,558.77	7,413.83
	e) Finance costs	276.59	302.59	298.96	1,148.44
	f) Depreciation and amortisation expense	508.19	517.29	559.74	2,093.63
	g) Other expenses	3,483.27	3,298.35	2,921.39	13,195.70
	Total expenses (a to g)	9,588.67	9,897.85	9,795.14	39,187.66
4	Profit before tax (2-3)	2,008.84	1,869.54	2,796.95	8,227.50
5	Exceptional Items Income / (expenses) (refer note 7 & 8)	907.14	(210.52)	-	696.62
6	Profit after Exceptional Items and before tax (4-5)	2,915.98	1,659.02	2,796.95	8,924.12
7	Tax expense				
	a) Current tax	377.45	311.19	497.57	1,460.72
	b) Deferred tax charge / (credit)	381.25	171.91	(631.74)	1,035.04
	Total tax expense (a+b)	758.70	483.10	(134.17)	2,495.76
8	Profit / (loss) for the period/year after tax (6-7)	2,157.28	1,175.92	2,931.12	6,428.36
9	Other Comprehensive Income				
(A)	i) Items that will not be reclassified to Profit or Loss				
	Income tax thereon	32.68	-	(112.48)	32.68
	Items that will be reclassified to Profit or Loss (net of tax)	(8.23)	-	32.75	(8.23)
(B)	ii) Income tax thereon	(2.69)	(0.30)	1.37	(5.00)
	Total other comprehensive income/(loss)	21.76	(0.30)	(78.36)	19.45
10	Total Comprehensive Income for the period/year (8+9)	2,179.04	1,175.62	2,852.76	6,447.81
11	Paid-up equity share capital (Face value ₹ 5/- per share)	1,433.53	1,443.57	1,458.45	1,433.53
12	Other equity (excluding revaluation reserve)				40,848.04
13	Earnings per equity share of ₹ 5 each (not annualised)				
	Earnings per equity share of ₹ 5 each before exceptional items	5.26	4.56	10.05	20.43
	a) ₹ Basic	5.21	4.53	10.05	20.27
	b) ₹ Diluted				
	Earnings per equity share of ₹ 5 each after exceptional items	7.49	4.04	10.05	22.13
	a) ₹ Basic	7.43	4.02	10.05	21.96
	b) ₹ Diluted				

SIGNED FOR IDENTIFICATION
BY 
S R B C & CO LLP
MUMBAI



See accompanying notes to the Standalone financial results

PARTICULARS		₹ in Lakhs	
		Standalone	
		Audited March 31, 2026	Audited March 31, 2025
ASSETS			
1	Non-current assets		
(a)	Property, plant and equipment	20,550.04	21,005.86
(b)	Capital work-in-progress	1,279.04	1,590.73
(c)	Right of use assets	492.78	619.34
(d)	Investment property (Refer note 4)	308.35	318.69
(e)	Goodwill	411.65	411.65
(f)	Other Intangible assets	229.58	227.94
(g)	Intangible assets under development	31.93	-
(h)	Investments		
	i) Investments in subsidiaries	1,120.06	320.06
	ii) Investments in an associate	-	-
(i)	Financial assets		
	i) Investments	41.94	48.63
	ii) Trade receivables	-	1,296.01
	iii) Loans	2,318.08	748.21
	iv) Other financial assets	533.04	502.92
(j)	Deferred tax assets (net)	1,835.91	2,864.40
(k)	Non-current tax assets	31.25	186.80
(l)	Other non-current assets	101.33	53.52
	Total Non-current assets	29,284.98	30,194.76
2	Current assets		
(a)	Inventories	13,065.56	9,447.82
(b)	Financial assets		
	i) Trade receivables	13,720.56	12,020.90
	ii) Cash and cash equivalents	887.97	1,849.52
	iii) Bank balances other than (ii) above	914.25	4,345.94
	iv) Loans	2.50	111.03
	v) Other financial assets	5,333.75	1,546.71
(c)	Other current assets	2,026.03	1,845.58
(d)	Contract Assets (Refer note 5)	-	884.30
	Total Current assets	35,950.62	32,051.80
	TOTAL ASSETS	65,235.60	62,246.56
EQUITY AND LIABILITIES			
1	EQUITY		
(a)	Equity Share capital	1,433.53	1,458.45
(b)	Other Equity	40,848.04	36,536.78
	Total Equity	42,281.57	37,995.23
2	Non-current liabilities		
(a)	Financial liabilities		
	i) Borrowings	789.94	1,504.76
	ii) Lease liabilities	318.08	444.37
	iii) Other financial liabilities	1,671.90	1,662.46
(b)	Provisions	1,019.08	780.59
(c)	Other non-current liabilities	7.89	16.22
	Total Non-current liabilities	3,806.89	4,408.40
3	Current liabilities		
(a)	Financial Liabilities		
	i) Borrowings	10,098.62	9,435.28
	ii) Lease liabilities	126.30	109.16
	iii) Trade payables		
	-Total outstanding dues of micro and small enterprises and;	208.25	387.86
	-Total outstanding dues of creditors other than micro enterprises and small enterprises	6,142.39	6,040.13
	iv) Other financial liabilities	717.99	431.20
(b)	Other current liabilities	1,640.73	2,817.12
(c)	Provisions	97.58	72.70
(d)	Current tax liabilities	115.28	441.05
(e)	Contract Liability (Refer note 5)	-	108.43
	Total Current liabilities	19,147.14	19,842.93
	TOTAL EQUITY AND LIABILITIES	65,235.60	62,246.56




NOTES:

1. Segment Information

Particulars	Standalone						₹ in Lakhs
	Quarter Ended		Year Ended		Year Ended		
	Audited	Unaudited	Audited	Audited	Audited	Audited	
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2026	March 31, 2025	
	Note 8		Note 8				
Segment revenue							
- Bulk drugs/chemicals	11,270.04	11,328.78	10,555.77	44,372.65	36,140.13		
- Property (Refer Note 4)	188.43	207.00	1,089.57	951.27	5,440.18		
- Unallocated (Refer Note 5)	139.04	231.61	946.75	2,091.24	2,640.64		
Total Income	11,597.51	11,767.39	12,592.09	47,415.16	44,220.95		
Segment results							
- Bulk drugs/chemicals (refer note 6)	2,124.17	1,930.86	2,043.98	8,260.73	3,843.96		
- Property	22.22	9.66	936.84	210.98	4,830.10		
- Unallocated (Net) (Refer Note 5)	139.04	231.61	115.09	904.23	187.90		
Total Profit before tax and finance cost	2,285.43	2,172.13	3,095.91	9,375.94	8,861.96		
- Finance costs	(276.59)	(302.59)	(298.96)	(1,148.44)	(1,419.92)		
Total Profit before Exceptional item and tax	2,008.84	1,869.54	2,796.95	8,227.50	7,442.04		
- Exceptional item (refer note 7 & 8)	907.14	(210.52)	-	696.62	-		
Total Profit before tax	2,915.98	1,659.02	2,796.95	8,924.12	7,442.04		
Segment Assets							
- Bulk drugs/chemicals	52,996.08	51,912.59	50,546.97	52,996.08	50,546.97		
- Property	856.88	1,954.42	1,306.54	856.88	1,306.54		
- Unallocated*	11,382.64	11,343.56	10,393.05	11,382.64	10,393.05		
Total Segment Assets	65,235.60	65,210.57	62,246.56	65,235.60	62,246.56		
Segment Liabilities							
- Bulk drugs/chemicals	8,971.77	8,933.80	8,832.67	8,971.77	8,832.67		
- Property	2,907.36	4,378.19	3,879.84	2,907.36	3,879.84		
- Unallocated*	11,074.90	11,205.26	11,538.82	11,074.90	11,538.82		
Total Segment Liabilities	22,954.03	24,517.25	24,251.33	22,954.03	24,251.33		

(*Refer note 5 for transfer of assets and liabilities pertaining to the Environment Division).



SIGNED FOR IDENTIFICATION

BY *H*

S R B C & CO LLP
MUMBAI

Statement of Cash Flows		₹ in Lakhs	
		Standalone	
Particulars		Year Ended	
		Audited March 31, 2026	Audited March 31, 2025
A)	CASH FLOWS FROM OPERATING ACTIVITIES		
	Profit after Exceptional Items and before tax	8,924.12	7,442.04
	Adjustments for:		
	Depreciation and amortisation expense	2,093.63	2,317.29
	Net unrealised foreign exchange (gain) / loss	(80.89)	148.73
	(Gain on sale) / write off of property, plant and equipment and investment property (net)	(173.37)	(3,961.86)
	Proceeds on sale of Investment Property	163.20	4,663.59
	Expected credit loss on financial asset	360.56	112.97
	Unwinding of interest on financial assets carried at amortised cost	(6.03)	(141.81)
	Share based payments to employees	295.30	-
	Finance costs	1,148.44	1,419.92
	Interest income	(564.49)	(312.02)
	Dividend income	(86.40)	(90.97)
	Liabilities / provisions no longer required written back (net)	(337.72)	(123.37)
	Gain on transfer of business to subsidiary (Refer note 5)	(41.31)	-
	Provisions no longer required written back of inventory (refer note 6)	(1,023.73)	(414.00)
	Exceptional Items	210.52	-
	Net (gain) / Loss on fair value changes of derivatives measured at FVTPL	(2.80)	(0.90)
	Operating Profit before working capital changes	10,879.03	11,059.61
	Movements in working capital:		
	Decrease / (Increase) in trade receivables	198.85	(5,021.46)
	(Increase) in inventories	(2,594.01)	(1,173.22)
	Decrease / (Increase) in other assets	2,124.30	(2,325.22)
	Increase in trade payables	259.00	1,196.22
	Increase in provisions	296.05	145.92
	(Decrease) in other liabilities	(1,269.65)	(222.04)
		9,893.56	3,659.81
	Income taxes net of refund (paid)	(1,630.95)	(277.12)
	Net cash generated from operations (A)	8,262.61	3,382.69
B)	CASH FLOWS FROM INVESTING ACTIVITIES		
	Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(3,031.24)	(2,213.36)
	Proceeds on sale of property, plant and equipment	10.92	1,925.09
	Repayment of loan given to employee /Intercompany deposits placed	18.30	371.25
	Interest received	392.96	384.50
	Intercompany deposits given /Loan given to employee	(1,400.00)	(8.00)
	Investments in subsidiary	(800.00)	-
	Proceeds from transfer of business to subsidiary	1,900.00	-
	Dividend received	86.40	90.97
	Bank Deposits (placed) / realised	(1,627.18)	(509.74)
	Net cash (used in) / generated investing activities (B)	(4,449.84)	40.71
C)	CASH FLOWS FROM FINANCING ACTIVITIES		
	Proceeds from non current borrowings	43.04	-
	Repayment of non current Borrowings	(1,784.86)	(3,334.45)
	Proceeds from shares issued by ESOP trust	0.65	246.72
	Proceeds / (Repayment) of current borrowing (net)	1,220.90	(247.98)
	Finance cost paid	(1,088.55)	(1,248.88)
	Repayment of Lease Liabilities	(148.71)	(144.97)
	Dividends paid	(729.22)	(361.18)
	Treasury shares acquired by ESOP trust	(1,728.19)	-
	Net cash (used in) financing activities (C)	(4,214.94)	(5,090.74)
	Net (decrease) in cash and cash equivalents (A)+(B)+(C)	(402.17)	(1,667.34)
	Net (decrease) in cash and cash equivalents	(402.17)	(1,667.34)
	Cash and cash equivalents at the beginning of the year	(311.65)	1,355.69
	Less: Decrease in cash & cash equivalents pursuant to transfer of environment business (refer note 5)	(150.00)	-
	Cash and cash equivalents at the end of the year	(863.82)	(311.65)
	Components of cash and cash equivalents		
	Cash on hand	30.89	21.23
	Balances with banks		
	In current accounts	857.08	1,828.29
	In deposit accounts with original maturity for less than 3 months	-	-
	Cash and cash equivalents	887.97	1,849.52
	Bank overdraft/Cash credit facilities	(1,751.79)	(2,161.17)
	Total cash and cash equivalents considered for cash flows	(863.82)	(311.65)

SIGNED FOR IDENTIFICATION
 BY 
SRBC & CO LLP
MUMBAI



- 2 The above audited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 26th May, 2026. The results of the Company are available for investors at www.fermentabiotech.com and www.bseindia.com.
- 3 These audited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended).
- 4 During the previous year ended March 31, 2025 the Company had sold part of its Investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and part of freehold land located at Village Takawe. In the current year the company has further sold part of its Investment in freehold land located at Village Takawe. Accordingly income on sale of such property for the quarter ended March 31, 2026, is ₹ Nil lakhs, quarter ended December 31, 2025, is ₹ Nil lakhs and quarter ended March 31, 2025, is ₹ 856.23 Lakhs and for the year ended March 31, 2026, is ₹ 162.89 lakhs and for the year ended March 31, 2025, is ₹ 4,457.88 lakhs has been recognized as income under the head revenue from operations pertaining to property segment.
- 5 The Board of Directors of the Company at its meeting held on September 19, 2025, approved the transfer of 'Environment Division as a going concern on a slump sale basis from October 01, 2025 to its wholly owned subsidiary i.e. Fermenta Environment Solutions Private Limited for a sales consideration of ₹ 1900 Lakhs. Accordingly on October 01, 2025, the Company has completed the transfer of Environment Division and net assets transferred pursuant to such slump sale has been accounted in the previous quarter ended December 31, 2025.
- 6 The excess of consideration over the carrying value of ₹ 41.31 lakhs has been recognised in the profit and loss account for the quarter ended December 31, 2025 ₹ 41.31 lakhs and year ended March 31, 2026 ₹ 41.31 lakhs. The transaction represents a reorganisation within the group and does not have any impact on the Company's financial performance for the period ended March 31, 2026. During the current year, the company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed. Accordingly provision of ₹ 1,023.73 lakhs has been reversed during the year (quarter ended March 31st, 2026 ₹ 316.78 Lakhs, December 31st, 2025 ₹ 201.40 Lakhs and year ended March 31, 2025 ₹ 414 Lakhs).
- 7 In the earlier years, the company had recognised provision against certain receivables and trade receivables. The company has recovered part amount of ₹ 907.14 lakhs against these provided balances and accordingly such provision has been reversed and recorded as an exceptional item in the current quarter.
- 8 The Government has notified the Code on Social Security, 2020 ("Social Security Code"); the Occupational Safety, Health and Working Conditions Code, 2020; the Industrial Relations Code, 2020 and the Code on Wages, 2019 (collectively, the "Labour Codes") on 21 November 2025. The Ministry of Labour & Employment notified Central Rules on 8 May 2026 however State Rules are yet to be notified. The Company has evaluated the impact of increased employee benefits obligations arising from the implementation of the Labour Codes based on its best judgment in consultation with external experts. Accordingly, the Company has recognised ₹ 210.52 lakhs for year ended March 31, 2026 (quarter December 31, 2025 ₹ 210.52 Lakhs) as mentioned above in accordance with Ind AS 19 - "Employee Benefits" and disclosed it as an Exceptional Item in the financial results for the quarter ended 31 December 2025 and year ended 31 March 2026.
- 9 The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and March 31, 2025 and the unaudited published year to date figures upto the nine months ended December 31, 2025 and December 31, 2024 of the relevant financial year which were subjected to a limited review by the statutory auditors.
- 10 The Board of Directors at their meeting held on May 26, 2026 have proposed a dividend of 75 % (₹ 3.75 per share) for the financial year ended 2025-2026. The payment of dividend is subject to approval of shareholders in the ensuing Annual General Meeting.
- 11 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification.

Place: Thane

Date : 26th May 2026

Prashant Nagre
Managing Director
DIN-09165447



Independent Auditor’s Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To
The Board of Directors of
Fermenta Biotech Limited****Report on the audit of the Consolidated Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date consolidated financial results of Fermenta Biotech Limited (“Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”) and its associate for the quarter ended March 31, 2026 and for the year ended March 31, 2026 (“Statement”), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”)

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements of the subsidiaries and associate, the Statement:

- i. includes the results of the following entities

S. No.	Name of the Entity	Relationship
1	Fermenta Biotech Limited	Parent
2	Fermenta Biotech (UK) Limited	Subsidiary
3	Fermenta Biotech GmbH	Subsidiary
4	Fermenta Biotech USA LLC	Subsidiary
5	Fermenta USA LLC	Subsidiary
6	Fermenta Environment Solutions Private Limited	Subsidiary
7	Health and Wellness India Private Limited	Associate

- ii. are presented in accordance with the requirements of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive loss and other financial information of the Group for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Consolidated Financial Results” section of our report. We are independent of the Group and its associate in accordance with the ‘Code of Ethics’ issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive loss and other financial information of the Group including its associate in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of their respective companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of their respective companies to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are also responsible for overseeing the financial reporting process of their respective companies.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.



S R B C & C O L L P

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associate of which we are the independent auditors to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matter

The accompanying Statement includes the financial statements and other financial information, in respect of:

- 3 subsidiaries, whose financial statements include total assets of Rs 3,631.62 lakhs as at March 31, 2026, total revenues of Rs 856.23 lakhs and Rs 4,920.81 lakhs, total net loss after tax of Rs. 303.51 lakhs and Rs.718.32 lakhs, total comprehensive loss of Rs. 299.56 lakhs and Rs. 714.37 lakhs, for the quarter and the year ended on that date respectively, and net cash outflows of Rs. 459.92 lakhs for the year ended March 31, 2026, as considered in the Statement which have been audited by their respective independent auditors.

The independent auditor's report on the financial statements and other financial information of these entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

The accompanying Statement includes unaudited financial statements and other unaudited financial information in respect of:

- 1 subsidiary, whose financial statements and other financial information reflect total assets of Rs 50.34 lakhs as at March 31, 2026, and total revenues of Rs Nil and Rs Nil, total net profit after tax of Rs (0.04) lakhs and Rs. 3.08 lakhs, total comprehensive loss of Rs. (0.04) lakhs and Rs. 3.08 lakhs, for the quarter and the year ended on that date respectively and net cash inflows of Rs. 3.08 lakhs for the year ended March 31, 2026, whose financial statements and other financial information have not been audited by their auditor
- 1 associate whose financial statements includes the Group's share of net profit of Rs. Nil and Rs Nil and Group's share of total comprehensive loss of Rs. Nil and Rs. Nil for the quarter and for the year ended March 31, 2026 respectively, as considered in the Statement whose financial statements and other financial information have not been audited by their auditor.



S R B C & COLLP

These unaudited financial statements and other unaudited financial information have been approved and furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary and an associate, is based solely on such unaudited financial results and other unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial statements and other financial information are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements and other financial information certified by the Management.

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

Poonam Tadarwal

per Poonam Tadarwal
Partner

Membership No.: 136454

UDIN: 26136454TFKJIY7284

Mumbai

May 26, 2026






Fermenta Biotech Limited
 CIN: I99999MH1951PLC008483
 Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
 Tel: +91-22-67980888, Fax: +91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Sr. No.	Particulars	Consolidated				₹ In Lakhs
		Quarter Ended		Year Ended		
		Audited March 31, 2026	Unaudited December 31, 2025	Audited March 31, 2026	Audited March 31, 2025	
1	Income	12,158.34	13,736.06	13,984.81	52,542.94	46,947.73
	a) Revenue from operations (refer note 4)	506.39	311.71	389.39	2,238.52	1,181.85
2	b) Other income	12,664.73	14,047.77	14,374.20	54,781.46	48,129.58
3	Total Income (a+b)			Note 8		
	Expenses					
	a) Cost of materials consumed (refer note 5)	3,713.66	5,124.24	5,322.21	14,875.93	12,994.93
	b) Purchases of stock-in-trade	147.65	991.60	1,987.48	4,364.20	5,965.61
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	311.24	(953.96)	(2,023.52)	(47.02)	(3,116.09)
	d) Employee benefits expense	2,132.77	2,077.20	1,688.73	8,259.43	6,510.43
	e) Finance costs	281.86	303.46	299.09	1,153.76	1,419.20
	f) Depreciation and amortisation expense	510.89	537.05	586.47	2,169.68	2,421.83
	g) Other expenses	3,852.81	4,000.61	3,315.57	15,107.01	13,612.89
4	Total expenses (a to g)	10,950.88	12,080.20	11,176.03	45,882.99	39,808.80
5	Profit before tax (2-3)	1,713.85	1,967.57	3,198.17	8,898.47	8,320.78
6	Exceptional items income / (expenses) (refer note 6 & 7)	907.14	(219.56)		687.58	
7	Profit after Exceptional items and before tax (4-5)	2,620.99	1,748.01	3,198.17	9,586.05	8,320.78
	Tax expense					
	a) Current tax	379.71	373.79	497.57	1,525.58	1,312.24
	b) Deferred tax charge / (credit)	381.25	171.91	(631.74)	1,035.04	(631.74)
8	Total tax expense (a+b)	760.96	545.70	(134.17)	2,560.62	680.50
9	Profit / (loss) for the period / year after tax but before share of profit of an associate (6-7)	1,860.03	1,202.31	3,332.34	7,025.43	7,640.28
10	Share of profit of an associate					
11	Net Profit after tax (8-9)	1,860.03	1,202.31	3,332.34	7,025.43	7,640.28
	Attributable to:					
	- Owners of the parent	1,918.99	1,268.01	3,438.96	7,176.53	7,686.18
	- Non-controlling interests	(58.96)	(65.70)	(106.62)	(151.10)	(45.90)
12	Other Comprehensive Income					
	Items that will not be reclassified to Profit or Loss					
	i) Remeasurements of defined benefit plan	36.63	-	(112.48)	36.63	(112.48)
	ii) Income tax thereon	(8.23)	-	32.75	(8.23)	32.75
	Items that will be reclassified to Profit or Loss					
	j) Exchange differences in translating the financials statements in foreign currency	(179.69)	(80.30)	(133.93)	(684.31)	(116.11)
	ii) Net fair value change in investment in equity instruments through other comprehensive income (net)	(2.69)	(0.30)	1.37	(5.00)	5.26
13	Total other comprehensive income	(153.98)	(80.60)	(212.29)	(660.91)	(190.58)
	Total Comprehensive Income for the period/year (10+12)	1,706.05	1,121.71	3,120.05	6,364.52	7,449.70
	Attributable to:					
	- Owners of the parent	1,765.01	1,187.41	3,226.67	6,515.62	7,495.60
	- Non-controlling interests	(58.96)	(65.70)	(106.62)	(151.10)	(45.90)
14	Paid-up equity share capital (Face value ₹ 5/- per share)	1,433.53	1,443.57	1,458.45	39,187.85	1,458.45
15	Other equity (excluding revaluation reserve)					
16	Earnings per equity share of ₹ 5 each (not annualised)					
	Earnings per equity share of ₹ 5 each before exceptional items					
	a) ₹ Basic	3.51	4.90	11.79	23.02	26.35
	b) ₹ Diluted	3.48	4.87	11.79	22.16	26.35
	Earnings per equity share of ₹ 5 each after exceptional items					
	a) ₹ Basic	6.66	4.36	11.79	24.70	26.35
	b) ₹ Diluted	6.61	4.34	11.79	24.51	26.35



SIGNED FOR IDENTIFICATION BY **AJ** S R B C & C O L L P MUMBAI

See accompanying notes to the Consolidated financial results

Balance Sheet as at March 31, 2026

₹ in Lakhs

PARTICULARS	Consolidated	
	Audited	Audited
	March 31, 2026	March 31, 2025
ASSETS		
1 Non-current assets		
(a) Property, plant and equipment	20,562.04	21,005.86
(b) Capital work-in-progress	1,279.04	1,590.73
(c) Right of use assets	492.77	619.33
(d) Investment property (Refer note 4)	308.34	318.71
(e) Goodwill	411.65	411.65
(f) Other Intangible assets	229.76	299.76
(g) Intangible assets under development	31.93	-
(h) Investments		
Investments in an associate	-	-
(i) Financial assets		
i) Investments	41.94	48.63
ii) Loans	115.94	21.78
iii) Other financial assets	534.52	502.92
(j) Deferred tax assets (net)	1,835.91	2,864.41
(k) Non-current tax assets	46.52	186.80
(l) Other non-current assets	101.33	53.53
Total Non-current assets	25,991.69	27,924.11
2 Current assets		
(a) Inventories	15,253.97	12,365.13
(b) Financial assets		
i) Trade receivables	11,159.08	9,522.64
ii) Cash and cash equivalents	3,169.46	2,823.96
iii) Bank balances other than (ii) above	964.85	4,345.93
iv) Loans	6.83	111.03
v) Other financial assets	5,324.74	1,537.76
(c) Other current assets	2,358.26	1,932.67
(d) Contract Assets (Refer note 5)	565.02	884.30
Total Current assets	38,802.21	33,523.42
TOTAL ASSETS	64,793.90	61,447.53
EQUITY AND LIABILITIES		
1 EQUITY		
(a) Equity Share capital	1,433.53	1,458.45
(b) Other Equity	39,187.85	34,808.77
Equity attributable to the owners of the Company	40,621.38	36,267.22
(c) Non-controlling interests	(566.79)	(415.69)
Total Equity	40,054.59	35,851.53
2 Non-current liabilities		
(a) Financial liabilities		
i) Borrowings	789.93	1,504.76
ii) Lease liabilities	318.08	444.37
iii) Other financial liabilities	1,671.90	1,662.46
(b) Provisions	1,074.08	780.59
(c) Other non-current liabilities	7.89	16.22
Total Non-current liabilities	3,861.88	4,408.40
3 Current liabilities		
(a) Financial Liabilities		
i) Borrowings	10,098.61	9,435.28
ii) Lease liabilities	126.30	109.16
iii) Trade payables		
-Total outstanding dues of micro and small enterprises and;	450.86	387.87
-Total outstanding dues of creditors other than micro enterprises and small enterprises	7,264.18	7,360.83
iv) Other financial liabilities	775.01	438.19
(b) Other current liabilities	1,703.99	2,817.13
(c) Provisions	101.21	89.66
(d) Current tax liabilities	184.27	441.05
(e) Contract Liability (Refer note 5)	173.00	108.43
Total Current liabilities	20,877.43	21,187.60
TOTAL EQUITY AND LIABILITIES	64,793.90	61,447.53



NOTES:

1. Segment Information

Particulars	Consolidated							
	Quarter Ended			Year Ended			Year Ended	
	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited	Audited
	March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025	March 31, 2025	March 31, 2025
Segment revenue								
- Bulk drugs/chemicals	12,399.63	13,280.03	12,337.89	12,337.89	51,472.17	40,048.76	40,048.76	
- Property (Refer Note 4)	188.43	207.01	1,089.57	1,089.57	951.27	5,440.18	5,440.18	
- Unallocated	76.67	560.73	946.74	946.74	2,358.02	2,640.64	2,640.64	
Total Income	12,664.73	14,047.77	14,374.20	14,374.20	54,781.46	48,129.58	48,129.58	
Segment results								
- Bulk drugs/chemicals (refer note 5)	2,053.73	2,204.68	2,445.26	2,445.26	9,331.20	4,722.32	4,722.32	
- Property	22.22	9.67	936.84	936.84	210.98	4,830.10	4,830.10	
- Unallocated (Net)	(80.24)	56.68	115.16	115.16	510.05	187.56	187.56	
Total Profit before tax and finance cost	1,995.71	2,271.03	3,497.26	3,497.26	10,052.23	9,739.98	9,739.98	
- Finance costs	(281.86)	(303.46)	(299.09)	(299.09)	(1,153.76)	(1,419.20)	(1,419.20)	
Total Profit before Exceptional item and tax	1,713.85	1,967.57	3,198.17	3,198.17	8,898.47	8,320.78	8,320.78	
- Exceptional item (refer note 6 & 7)	907.14	(219.56)	-	-	687.58	-	-	
Total Profit before tax	2,620.99	1,748.01	3,198.17	3,198.17	9,586.05	8,320.78	8,320.78	
Segment Assets								
- Bulk drugs/chemicals	52,329.04	48,292.67	49,747.88	49,747.88	52,329.04	49,747.88	49,747.88	
- Property	856.88	1,954.42	1,306.54	1,306.54	856.88	1,306.54	1,306.54	
- Unallocated	11,607.98	13,598.79	10,393.11	10,393.11	11,607.98	10,393.11	10,393.11	
Total Segment Assets	64,793.90	63,845.88	61,447.53	61,447.53	64,793.90	61,447.53	61,447.53	
Segment Liabilities								
- Bulk drugs/chemicals	9,903.30	8,971.43	10,177.29	10,177.29	9,903.30	10,177.29	10,177.29	
- Property	2,907.36	4,378.19	3,879.84	3,879.84	2,907.36	3,879.84	3,879.84	
- Unallocated	11,928.65	11,598.29	11,538.88	11,538.88	11,928.65	11,538.88	11,538.88	
Total Segment Liabilities	24,739.31	24,947.91	25,596.01	25,596.01	24,739.31	25,596.01	25,596.01	

SIGNED FOR IDENTIFICATION

BY

AS

S R B C & CO LLP
MUMBAI




Statement of Cash Flows		₹ In Lakhs	
		Consolidated	
Particulars		Year Ended	
		Audited March 31, 2026	Audited March 31, 2025
A)	CASH FLOWS FROM OPERATING ACTIVITIES		
	Profit after Exceptional Items and before tax	9,586.05	8,320.78
	Adjustments for:		
	Depreciation and amortisation expense	2,169.68	2,421.83
	Net unrealised foreign exchange loss /(gain)	(85.61)	318.44
	(Gain on sale) / write off of property, plant and equipment and investment property (net)	(173.38)	(3,961.86)
	Proceeds on sale of Investment Property	162.89	4,663.59
	Expected credit loss on financial asset	374.75	117.24
	Share based payments to employees	295.30	-
	Finance costs	1,153.76	1,419.20
	Interest income	(475.26)	(275.36)
	Dividend income	(86.40)	(90.97)
	Unwinding of interest on financial assets carried at amortised cost	(6.03)	(141.81)
	Liabilities / provisions no longer required written back (net)	(342.32)	(172.71)
	Provisions no longer required written back of inventory (refer note 5)	(1,023.73)	(414.00)
	Exceptional Items	219.56	-
	Net (gain) / loss on fair value changes of derivatives measured at FVTPL	(2.80)	(0.90)
	Operating Profit before working capital changes	11,766.46	12,203.47
	Movements in working capital:		
	(Increase) in trade receivables	(932.78)	(3,415.77)
	(Increase) in inventories	(1,674.61)	(3,212.71)
	Decrease / (Increase) in other assets	1,312.19	(2,481.17)
	Increase in trade payables	1,093.33	1,378.97
	Increase in provisions	341.67	115.88
	(Decrease) in other liabilities	(980.81)	(221.35)
		10,925.45	4,367.32
	Income taxes refund net of payment/(paid)	(1,642.08)	(277.12)
	Net cash generated from operations (A)	9,283.37	4,090.20
B)	CASH FLOWS FROM INVESTING ACTIVITIES		
	Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(3,033.46)	(2,213.32)
	Proceeds on sale of property, plant and equipment	10.91	1,925.09
	Repayment of loan given to employee /Intercorporate deposits placed	10.04	379.41
	Interest received	304.27	311.64
	Dividend received	86.40	90.97
	Bank Deposits (placed) / realised	(1,677.79)	(509.74)
	Net cash (used in) Investing activities (B)	(4,299.63)	(15.95)
C)	CASH FLOWS FROM FINANCING ACTIVITIES		
	Proceeds from non current borrowings	43.03	-
	Repayment of non current Borrowings	(1,784.86)	(3,334.45)
	Treasury shares acquired by ESOP trust	(1,728.19)	-
	Proceeds on issue of equity share on stock option exercise	0.65	246.72
	Proceeds / (Repayment) of current borrowings (net)	1,220.90	(247.98)
	Finance cost paid	(1,102.46)	(1,244.72)
	Repayment of Lease Liabilities	(148.71)	(144.97)
	Dividends paid	(729.22)	(361.18)
	Net cash (used in) financing activities (C)	(4,228.86)	(5,086.58)
	Net increase/(decrease) in cash and cash equivalents (A)+(B)+(C)	754.88	(1,012.34)
	Cash and cash equivalents at the beginning of the year	662.79	1,675.13
	Cash and cash equivalents at the end of the year	1,417.67	662.79
	Components of cash and cash equivalents		
	Cash on hand	30.89	21.23
	Balances with banks		
	In current accounts	3,138.57	2,802.73
	In deposit accounts with original maturity for less than 3 months	-	-
	Cash and cash equivalents	3,169.46	2,823.96
	Bank overdraft/Cash credit facilities	(1,751.79)	(2,161.17)
	Total cash and cash equivalents considered for cash flows	1,417.67	662.79



- 2 The above audited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 26th May, 2026. The results of the Company are available for investors at www.fermentabiotech.com and www.bseindia.com.
- 3 These audited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year ended March 31, 2025 the parent Company had sold part of its investment in Property consisting of commercial property in Ceejay House, Worli, Mumbai and part of freehold land located at Village Takawe. In the current year the parent company has further sold part of its investment in freehold land located at Village Takawe and accordingly income on sale of such property for the quarter ended March 31, 2026, is ₹ Nil lakhs, quarter ended December 31, 2025, is ₹ Nil lakhs and quarter ended March 31, 2025, is ₹ 856.23 Lakhs and for the year ended March 31, 2026, is ₹ 162.89 lakhs and for the year ended March 31, 2025, is ₹ 4,457.88 lakhs has been recognized as income under the head revenue from operations pertaining to property segment.
- 5 During the current year, the parent company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed. Accordingly provision of ₹ 1,023.73 lakhs has been reversed during the year (quarter ended March 31st, 2026 ₹ 316.78 Lakhs, December 31st, 2025 ₹ 201.40 Lakhs and year ended March 31, 2025 ₹ 414 Lakhs).
- 6 The Government has notified the Code on Social Security, 2020 ("Social Security Code"); the Occupational Safety, Health and Working Conditions Code, 2020; the Industrial Relations Code, 2020 and the Code on Wages, 2019 (collectively, the "Labour Codes") on 21 November 2025. The Ministry of Labour & Employment notified Central Rules on 8 May 2026 however State Rules are yet to be notified. The group has evaluated the impact of increased employee benefits obligations arising from the implementation of the Labour Codes based on its best judgment in consultation with external experts. Accordingly, the group has recognised ₹ 219.56 lakhs for year ended March 31, 2026 (quarter December 31, 2025 ₹ 219.56 Lakhs) as mentioned above in accordance with Ind AS 19 - "Employee Benefits" and disclosed it as an Exceptional Item in the financial results for the quarter ended 31 December 2025 and year ended 31 March 2026.
- 7 In the earlier years, the parent company had recognised provision against certain receivables and trade receivables. The parent company has recovered part amount of ₹ 907.14 lakhs against these provided balances and accordingly such provision has been reversed and recorded as an exceptional items in the current quarter.
- 8 The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and March 31, 2025 and the unaudited published year to date figures upto the nine months ended December 31, 2025 and December 31, 2024 of the relevant financial year which were subjected to a limited review by the statutory auditors.
- 9 The Board of Directors at their meeting held on May 26, 2026 have proposed a dividend of 75% (₹ 3.75 per share) for the financial year ended 2025-2026. The payment of dividend is subject to approval of shareholders in the ensuing Annual General Meeting.
- 10 Figures of the previous periods have been regrouped/ reclassified wherever necessary to confirm to the current period classification.

Place: Thane

Date : 26th May 2026



Prashant Nagre
Managing Director
DIN-09165447

